Good day, welcome to the Intellia Therapeutics, Inc. 2026 Annual Meeting of Stockholders. I would now like to turn the conference over to Dr. Frank Verwiel, Chairperson of the c ompany's Board of Directors, to proceed with the 2026 Annual Meeting of Stockholders. Dr. Verwiel, please go ahead. Thank you. Good morning. I am Dr. Frank Verwiel, Chairperson of the Board of Intellia Therapeutics, Inc., I will act as the chairperson of this meeting. I am pleased to welcome you to Intellia 2026 Annual Meeting of Stockholders. Before I call the meeting to order, I would like to introduce you to the members of our Board and our executive team who are with us today. The other members of the Board with us today are Muna Bhanji, Bill Chase, Dr. Fred Cohen, Brian Goff, Dr. Jesse Goodman, Dr. Georgia Keresty, and Dr. John Leonard, our President and Chief Executive Officer. The other officers and members of the management of the company with us today are James Basta, General Counsel and Corporate Secretary, Dr. Eliana Clark, Chief Technology Officer, Edward Dulac, Chief Financial Officer, Dr. David Lebwohl, Chief Medical Officer, Dr. Birgit Schultes, Chief Scientific Officer, Michael P. Dube, Chief Accounting Officer, Daniel Lev, Associate General Counsel. Mr. Basta will act as the secretary, Mr. Lev will act as the Inspector of Election for this meeting. Mr. Lev has taken and subscribed to the customary oath of office to execute his duties with strict impartiality, which will be filed with the records of the meeting. I also would like to introduce James Horan of Deloitte & Touche LLP, the company's independent registered public accounting firm, who's available to respond to appropriate questions. T he meeting will now officially come to order. We propose to proceed with the formal business of the meeting as set forth in the company's 2026 Notice of Annual Meeting and Proxy Statement. We request that if you have questions, please submit them following the instructions provided on the virtual meeting screen and described in the rules of conduct. Will the secretary please report at this time on the mailing of the notice for this meeting and stockholders list? I have at this meeting a complete list of the stockholders of record of the company at the close of business on April 10th, 2026, record date for this meeting. I also have an affidavit certifying that commencing on April 30th, 2026, the notice of Internet availability of proxy materials was deposited in United States mail to all stockholders of record as of April 10th, 2026. Will the secretary please report at this time with respect to the existence of a quorum? I have been informed by the Inspector of Elections that proxies have been received for 88,862,666 of the 120,464,338 shares of common stock outstanding on the record date, which represents approximately 73.8% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today. We may now carry out the official business of the meeting. Are there any additional proxies to be submitted to the Inspector of Elections at this time? Mr. Verwiel, there have been no additional proxies submitted to me. Thank you. We will now proceed with the formal business of this meeting. The following proposals are to be considered by our stockholders at this meeting. Proposal one is the election of three Class I directors to our board of directors, each to serve until 2029 Annual Meeting of Stockholders, until their successor has been duly elected and qualified, or until their early death, resignation, or removal. Proposal two is the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. Proposal three is the approval on a non-binding advisory basis of the compensation of our named executive officers. Those were the final proposals for today's meeting. The secretary will now describe the voting procedures. The time is now 9:04 A.M. Eastern Time on Tuesday, June 11th, 2026. The polls are now open for voting on the proposals described by the chairperson. All Intellia stockholders entitled to vote at this meeting have the ability to do so online. You do not need to vote again if you have already voted your proxy online, by telephone, or by mail and do not wish to change your vote. However, if you have either not voted already or if you want to change your previous vote, you may do so now in accordance with the instructions on your virtual meeting screen and described in the rules and guidelines. The time is now 9:06 A.M. Eastern Time, and the polls are now closed for voting. May we have the results of the voting? The report of the Inspector of Elections covering the proposals presented at this meeting is as follows. Proposal one for the election of Muna Bhanji, Brian Goff, and Jesse Goodman as Class I Directors of the company has been approved. Proposal two for the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31st, 2026, has been approved. Proposal three for the approval on a non-binding advisory basis of the compensation of our named executive officers has been approved. Thank you. There being no other business to properly come before this meeting, let us pause for a moment to compile any questions that have been submitted via the online portal regarding only the matters that have been discussed in this formal meeting. Will the secretary please advise if we have any questions? We have no questions appropriately related to the purpose of this meeting. There being no other business to properly come before this meeting, this meeting is now adjourned. Thank you for attending Intellia Therapeutics 2026 Annual Meeting of Stockholders. The 2026 Annual Meeting of Stockholders has now concluded. Thank you for attending today's meeting.